Other studies have shown similar results, with CD274 (PD-L1), PDCD1 (PD-1), and PDCD1LG2 (PD-L2) significantly upregulated in high-risk groups (Wang et al., 2022b) which helps identify GC patients who might benefit from immune checkpoint therapy. Here, PDCD1LG2 is linked to gastric cancer.